In the era of personalized medicine, the introduction of translational studies in clinical trials has substantially increased their costs, but provides the possibility of improving the productivity of trials with a better selection of recruited patients. With the overall goal of creating a roadmap to improve translational design for future gynecological cancer trials and of defining translational goals, a main discussion was held during a brainstorming day of the Gynecologic Cancer InterGroup (GCIG) Translational Research Committee and overall conclusions are here reported. A particular emphasis was dedicated to the new frontier of the immunoprofiling of gynecological cancers. The discussion pointed out that to maximize patients' benefit, translational studies should be integral to clinical trial design with standardization and optimization of procedures including a harmonization program of Standard Operating Procedures. Pathology-reviewed sample collection should be mandatory and ensured by dedicated funding. Biomarker validation and development should be made public and transparent to ensure rapid progresses with positive outcomes for patients. Guidelines/templates for patients' informed consent are needed. Importantly for the public, recognized goals are to increase the involvement of advocates and to improve the reporting of translational data in a forum accessible to patients.
[1]Fdn IRCCS Ist Nazl Tumori Milano, Dept Res, I-20133 Milan, Italy;
[2]Fudan Univ, Zhongshan Hosp, Dept Obstet & Gynecol, Shanghai 200032, Peoples R China;
[3]Univ Edinburgh, Canc Res UK Ctr, MRC IGMM, Edinburgh EH4 2XU, Midlothian, Scotland;
[4]Med Univ Vienna, Gen Hosp Vienna, Dept Gynaecol Oncol, A-1090 Vienna, Austria;
[5]Philipps Univ Marburg, Coordinating Ctr Clin Trials, D-35043 Marburg, Germany;
[6]Univ Med Ctr Groningen, Dept Obstet & Gynecol, NL-9700 RB Groningen, Netherlands;
[7]Leiden Univ, Med Ctr, Dept Radiat Oncol, NL-2333 ZA Leiden, Netherlands;
[8]Inst Curie, Dept Drug Dev & Innovat, F-75005 Paris, France;
[9]EORTC, B-1200 Brussels, Belgium;
[10]Roswell Pk Canc Inst, Dept Biostat & Bioinformat, Buffalo, NY 14203 USA;
[11]Saitama Med Univ, Int Med Ctr, Dept Gynecol Oncol, Saitama 13971, Japan;
[12]Univ Tokyo, Grad Sch Med, Dept Obstet & Gynecol, Tokyo 1138654, Japan;
[13]Imperial Coll London, Dept Surg & Canc, Div Canc, London SW7 2AZ, England;
[14]NCI, Clin Invest Branch, Canc Therapy Evaluat Program, Rockville, MD 20852 USA;
[15]Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med,Div Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada;
[16]Univ Toronto, Sunnybrook Odette Canc Ctr, Div Med Oncol, Toronto, ON M4N 3M5, Canada;
[17]Queen Elizabeth Univ Hosp, Dept Pathol, Glasgow G51 4TR, Lanark, Scotland;
[18]Gynecol Canc InterGroup, Operat, Kingston, ON K7K 7A6, Canada;
[19]Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia
(8.0+极速模式)